TransUnion
TRU
$70.57
-0.13%
TransUnion is one of the three major consumer credit reporting agencies globally, operating within the financial data and analytics industry. Its core business involves aggregating consumer credit information to produce credit reports and scores, while also providing fraud detection, marketing, and advanced analytical services to businesses across over 30 countries. As a dominant incumbent in a highly concentrated market, the company's competitive identity is that of an essential data infrastructure provider, leveraging its vast proprietary dataset to serve lenders, insurers, and other enterprises. The current investor narrative is shaped by its strategic expansion into international markets, highlighted by the recent acquisition of a majority stake in Mexico's Buró de Crédito, and ongoing debates about its ability to navigate economic cycles, manage costs, and compete against fintech disruptors leveraging AI, as reflected in recent news comparing its position to AI-driven rivals.…
TRU
TransUnion
$70.57
Related headlines
TRU 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransUnion's 12-month outlook, with a consensus price target around $91.74 and implied upside of +30.0% versus the current price.
Average Target
$91.74
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$56 - $92
Analyst target range
A modest group of six analysts provides coverage for TransUnion. The consensus sentiment appears neutral to cautiously optimistic, with recent ratings including 'Overweight' from Morgan Stanley and Wells Fargo, 'Buy' from Stifel and Needham, and 'Neutral' or 'Equal Weight' from Goldman Sachs and Barclays. The average target price implied by the estimated EPS of $7.77 and a forward P/E of 12.65x is approximately $98.29, which suggests a significant implied upside of roughly 39% from the current price of $70.66. The target price range is wide, with a low EPS estimate of $7.32 and a high of $8.26, translating to a price range of roughly $92.60 to $104.50 based on the same forward multiple. The high target likely assumes successful execution on international growth, margin stabilization, and the accretive impact of recent acquisitions. The low target likely factors in continued economic headwinds impacting credit demand, competitive pressures, and integration risks. The recent institutional rating actions have been largely reiterations, with no major downgrades or upgrades in 2026, indicating a wait-and-see stance among analysts following the stock's decline and recent corporate developments.
Bulls vs Bears: TRU Investment Factors
The evidence is currently balanced but leans bearish in the near term due to overwhelming negative price momentum, margin compression, and high short interest. The bullish case rests almost entirely on the forward-looking valuation reset and analyst confidence in a significant earnings recovery. The single most important tension in the investment debate is whether the company can achieve the projected forward EPS of $7.77 to justify its current price. If earnings meet or exceed this target, the stock is deeply undervalued at a 12.65x forward P/E. If earnings disappoint, the elevated trailing P/E of 36.6x and the technical breakdown suggest substantial further downside.
Bullish
- Strong Forward P/E of 12.65x: The forward P/E of 12.65x, based on a consensus EPS of $7.77, represents a significant discount to the trailing P/E of 36.6x and implies a valuation reset that prices in a sharp earnings recovery. This forward multiple is attractive for a company with a stable, oligopolistic market position and strong cash generation.
- Robust Free Cash Flow Generation: The company generated $222.8 million in free cash flow last quarter and $661.6 million over the trailing twelve months, supporting a healthy current ratio of 1.75. This provides ample financial flexibility to service its debt (D/E of 1.16), fund dividends, and execute strategic acquisitions like the Buró de Crédito stake.
- Analyst Target Implies 39% Upside: The average analyst target price derived from the forward P/E and EPS is approximately $98.29, implying a 39% upside from the current price of $70.66. The analyst consensus is neutral-to-positive, with four 'Buy' or 'Overweight' ratings out of six, indicating professional confidence in the forward earnings story.
- Strategic International Expansion: The recent acquisition of a majority stake in Mexico's Buró de Crédito strengthens its Latin American footprint and offers a clear path for growth outside the mature U.S. market. International revenue of $255.8M in Q4 2025 represents a key growth vector.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 16.36% over the past year, dramatically underperforming the S&P 500's 27.88% gain, with a relative strength of -44.24. Trading just 15% above its 52-week low of $64.51, the chart shows persistent negative momentum with no sign of a reversal, reflecting deep investor skepticism.
- Operating Margin Compression: The operating margin has compressed from 23.22% in Q1 2025 to 17.38% in Q4 2025, a decline of nearly 600 basis points. This indicates rising costs or a less profitable revenue mix, pressuring the bottom line despite top-line growth.
- High Beta and Earnings Volatility: With a beta of 1.571, the stock is 57% more volatile than the market, amplifying downside risk in bearish conditions. This volatility is compounded by earnings instability, with trailing EPS at just $0.03, creating a high degree of uncertainty around the forward $7.77 estimate.
- Elevated Short Interest: A short ratio of 3.75 indicates significant bearish sentiment and potential for a squeeze, but more importantly, it reflects a market bet that the company's forward earnings recovery will not materialize or that its competitive position is eroding.
TRU Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -16.36%, significantly underperforming the broader market, which is up 27.88% over the same period. Currently trading at $70.66, the price is near the lower end of its 52-week range of $64.51 to $99.39, positioning it at approximately 15% above its 52-week low. This proximity to the low suggests the stock is in a zone of potential value but also reflects persistent negative momentum and investor skepticism, requiring a clear catalyst for reversal. Short-term momentum remains weak and aligned with the longer-term downtrend, with the stock down 4.50% over the past month and 7.27% over the past three months. This underperformance is stark when compared to the S&P 500, which gained 4.84% and 8.15% over the same periods, respectively, as indicated by the relative strength figures of -9.34 and -15.42. The lack of divergence suggests no near-term buying pressure is emerging to challenge the prevailing bearish trend. Key technical support is clearly defined at the 52-week low of $64.51, while resistance sits at the 52-week high of $99.39. A decisive break below support could signal a new leg down, whereas a sustained move above the recent trading range's upper bound near $87 (from late December) would be needed to suggest a trend reversal. The stock's beta of 1.571 indicates it is approximately 57% more volatile than the market, which is critical for risk management, as it implies amplified moves both up and down in volatile market conditions.
Beta
1.57
1.57x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$65-$99
Price range past year
Annual Return
-15.1%
Cumulative gain past year
| Period | TRU Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +5.1% |
| 3m | -5.0% | +8.3% |
| 6m | -16.9% | +10.4% |
| 1y | -15.1% | +29.6% |
| ytd | -15.3% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TRU Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration on a sequential basis. The most recent quarterly revenue (Q4 2025) was $1.171 billion, representing a 12.98% year-over-year increase. However, examining the quarterly sequence from Q1 2025 ($1.096B) to Q4 2025 shows revenue peaked in Q3 2025 at $1.170B, with Q4 showing only a slight sequential uptick. The U.S. Markets segment, contributing $918.9 million, remains the dominant driver, while the International segment contributed $255.8 million, highlighting the company's growth potential outside its core market. Profitability is present but margins have shown volatility. Net income for Q4 2025 was $101.2 million, translating to a net margin of 8.64%. The gross margin for the quarter was a healthy 59.35%, consistent with the company's data-centric business model. However, operating income of $203.6 million yields an operating margin of 17.38%, which has compressed from the 23.22% reported in Q1 2025, indicating potential pressure from operating expenses or mix shifts. The balance sheet and cash flow position indicate moderate leverage but solid cash generation. The debt-to-equity ratio stands at 1.16, indicating a leveraged but manageable capital structure. The company generated $319.5 million in operating cash flow and $222.8 million in free cash flow in its latest quarter, contributing to a trailing twelve-month free cash flow of $661.6 million. This strong cash generation, alongside a current ratio of 1.75, supports financial flexibility for debt servicing, dividends, and strategic investments like the recent acquisition in Mexico.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$661600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TRU Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 36.60x, while the forward P/E is significantly lower at 12.65x. This substantial gap implies the market is pricing in a sharp recovery in earnings, with analyst consensus expecting EPS to grow from a trailing $0.03 (based on key metrics data) to a forward estimate of $7.77. Compared to the broader 'Consulting Services' industry, the trailing P/E of 36.6x is difficult to contextualize without a specific industry average provided in the data, but the forward multiple of 12.65x appears more reasonable if the earnings recovery materializes. The premium or discount justification hinges entirely on the company's ability to meet these elevated forward earnings expectations. Historically, the stock's own valuation has compressed significantly. The current trailing P/E of 36.6x is below the historical high from Q3 2024 of 74.91x but above the low from Q1 2021 of 5.59x. More recently, the P/E has declined from 41.23x at the end of Q4 2025 to its current level, suggesting the market has already de-rated the stock due to earnings pressure and the negative price trend. Trading near the middle of its recent historical range indicates the market has balanced concerns about near-term fundamentals with longer-term earnings power.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -11x~103x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TransUnion faces financial risk from its moderate leverage, with a debt-to-equity ratio of 1.16, which could pressure cash flow in a rising rate environment. Operational margin compression is a clear concern, with the operating margin declining from 23.22% to 17.38% over the past year, potentially eroding profitability despite 12.98% YoY revenue growth. Furthermore, earnings are highly volatile, with trailing EPS at $0.03, creating execution risk around the forward EPS target of $7.77 that the entire bullish thesis depends upon.
Market & Competitive Risks: The stock's primary market risk is valuation compression. Despite the attractive forward P/E, the elevated trailing P/E of 36.6x leaves it vulnerable to further de-rating if growth falters. Its beta of 1.571 means it will experience amplified moves in any market downturn. Competitively, the threat from fintech and AI-driven lending platforms, as noted in recent news, could gradually erode its core analytics and scoring business, forcing increased R&D spend. The stock's severe underperformance (-44% relative strength vs. SPY) also indicates it is out of favor and susceptible to sector rotation away from challenged names.
Worst-Case Scenario: The worst-case scenario involves a recessionary environment that curtails credit demand, combined with the company missing its forward earnings estimates due to persistent margin pressure and integration issues from its Mexican acquisition. This could trigger a wave of analyst downgrades and a flight from a high-beta stock. In this adverse scenario, the stock could realistically re-test its 52-week low of $64.51, representing a downside of approximately -9% from the current price. A breach of that level could see a fall toward the $60 range, implying a total potential loss of 15-20% from current levels.

